FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase

BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular t...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology Vol. 166; no. 4; pp. 1411 - 1418
Main Authors: Spijkers, Léon JA, Alewijnse, Astrid E, Peters, Stephan LM
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-06-2012
Nature Publishing Group
Subjects:
Rat
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A2. CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase.
AbstractList BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A2. CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase. [PUBLICATION ABSTRACT]
BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A2. CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase.
FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age-matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720-induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS-induced contractions) they were endothelium-dependent and mediated by thromboxane A₂. These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase.
BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated that this drug modestly increases BP. We previously showed that inhibition of sphingosine kinase increases vascular tone and BP in hypertensive, but not normotensive rats. Since FTY720 is reported to have inhibitory effects on sphingosine kinase, we investigated whether FTY720 increases vascular tone and BP only in hypertensive rats via this mechanism. EXPERIMENTAL APPROACH The contractile and BP modulating effects of FTY720 were studied in vivo and ex vivo (wire myography) in age‐matched normotensive Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). KEY RESULTS Oral administration of FTY720 induced an increase in mean arterial pressure in SHR, whereas a decrease in BP was observed in WKY rats, as measured 24 h after administration. Similar to the sphingosine kinase inhibitor dimethylsphingosine (DMS), FTY720 induced large contractions in isolated carotid arteries from SHR, but not in those from WKY. In contrast, the phosphorylated form of FTY720 did not induce contractions in isolated carotid arteries from SHR. FTY720‐induced contractions were inhibited by endothelium denudation, COX and thromboxane synthase inhibitors, and by thromboxane receptor antagonism, indicating that (like DMS‐induced contractions) they were endothelium‐dependent and mediated by thromboxane A 2 . CONCLUSIONS AND IMPLICATIONS These data demonstrate that FTY720 increases vascular tone and BP only in hypertensive rats, most likely as a result of its inhibitory effect on sphingosine kinase.
Author Peters, Stephan LM
Spijkers, Léon JA
Alewijnse, Astrid E
Author_xml – sequence: 1
  givenname: Léon JA
  surname: Spijkers
  fullname: Spijkers, Léon JA
– sequence: 2
  givenname: Astrid E
  surname: Alewijnse
  fullname: Alewijnse, Astrid E
– sequence: 3
  givenname: Stephan LM
  surname: Peters
  fullname: Peters, Stephan LM
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25934376$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22251137$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAUhS3Uik4Lr4AsIaSySPBv4ixAohVtkSrBoixYWY5jdzxk7NROhs4L8Nw4zDDADi9sS_e75xzpnIIjH7wBAGJU4nzerErM6qrgVOCSIExKhEXFy8cnYHEYHIEFQqguMBbiBJymtEIoD2v-FJwQQjjGtF6AH1d3X2uC4Ll1_j70bh2619B5HY1KJsGNSnrqVYRjDgCV72Dbh9DBIZqUpmgyCtMQ_Ki8CVPqt3C5HUwcjU9uY2BUY9ZwKmNL17rRBQ-DzRvL2S25rPnN-ez0DBxb1SfzfP-egS9XH-4ub4rbT9cfL9_fFpo3ghdWM8sEYZWmCDUdEqyhqGOYtMpaq7t8K8NpY1pViY6yrjG1tkoLIypCsaVn4N1Od5jatem08WNUvRyiW6u4lUE5-e_Eu6W8DxtJGa4Zr7LAy71ADA-TSaNchSn6nFliznjNCUI8U2JH6RhSisYeHDCSc4NyJeei5FyUnBuUvxqUj3n1xd8JD4u_K8vAqz2Qu1G9jcprl_5wvKGM1nPStzvuu-vN9r8DyIvPN_OP_gRclr0R
CODEN BJPCBM
CitedBy_id crossref_primary_10_1093_biolre_ioab012
crossref_primary_10_1371_journal_pone_0162029
crossref_primary_10_1016_j_jaut_2016_03_012
crossref_primary_10_1111_nmo_13372
crossref_primary_10_1016_j_ejphar_2018_10_027
crossref_primary_10_1161_HYPERTENSIONAHA_117_09088
crossref_primary_10_1371_journal_pone_0097196
crossref_primary_10_1007_s13760_017_0794_7
crossref_primary_10_1016_j_dld_2024_03_010
crossref_primary_10_1124_jpet_116_236208
crossref_primary_10_1111_bph_14381
crossref_primary_10_1124_jpet_116_233205
crossref_primary_10_1111_wrr_12685
crossref_primary_10_2174_1871527319666200825164123
crossref_primary_10_3389_fcvm_2022_915961
crossref_primary_10_1016_j_phrs_2020_104793
crossref_primary_10_1161_HYPERTENSIONAHA_117_10655
Cites_doi 10.1212/WNL.0b013e3181e3972b
10.1111/j.1476-5381.2009.00451.x
10.1152/ajpheart.01089.2002
10.1124/dmd.110.035907
10.1016/j.phrs.2010.09.002
10.1111/j.1476-5381.2011.01260.x
10.1056/NEJMoa0907839
10.1016/j.ejphar.2008.02.089
10.1161/01.RES.41.1.19
10.1042/BST0350908
10.1002/bdd.535
10.1007/s10059-010-0042-y
10.1038/sj.bjp.0707581
10.1182/blood-2006-03-011437
10.1111/j.1476-5381.2011.01649_1.x
10.1074/jbc.M805186200
10.1038/nrc2875
10.1007/s10059-010-0041-z
10.1161/01.RES.0000164321.91452.00
10.1084/jem.20091343
10.1007/s00395-008-0744-x
10.5414/CPP45098
10.1056/NEJMoa0909494
10.1371/journal.pone.0029222
10.1002/jbt.20193
10.1177/1352458509357065
10.1074/jbc.M307687200
10.1177/0091270006289853
10.1016/j.cellsig.2010.05.022
10.1371/journal.pone.0021817
10.1021/jm050242f
10.1038/nrm2329
10.1124/jpet.103.062828
ContentType Journal Article
Copyright 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society
2015 INIST-CNRS
2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society 2012
Copyright_xml – notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society
– notice: 2015 INIST-CNRS
– notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
– notice: 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society 2012
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TK
K9.
NAPCQ
5PM
DOI 10.1111/j.1476-5381.2012.01865.x
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1476-5381
EndPage 1418
ExternalDocumentID 3376261041
10_1111_j_1476_5381_2012_01865_x
22251137
25934376
BPH1865
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GJ
05W
0R~
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
3V.
4.4
52U
52V
53G
5GY
6J9
7RV
7X7
8-0
8-1
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
A00
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCUV
ABDBF
ABPVW
ABQWH
ABUWG
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
B0M
BAFTC
BAWUL
BBNVY
BENPR
BFHJK
BHBCM
BHPHI
BKEYQ
BMXJE
BPHCQ
BRXPI
BVXVI
C45
CAG
CCPQU
COF
CS3
DCZOG
DIK
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
ECV
EJD
EMB
EMK
EMOBN
ENC
ESX
EX3
F5P
FUBAC
FYUFA
G-S
GODZA
GX1
H.X
HCIFZ
HGLYW
HMCUK
HYE
HZ~
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LK8
LOXES
LSO
LUTES
LW6
LYRES
M1P
M7P
MEWTI
MK0
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NAPCQ
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P4E
PQQKQ
PROAC
PSQYO
Q.N
Q2X
QB0
RIG
ROL
RPM
RWI
SJN
SUPJJ
SV3
TEORI
TR2
TUS
UKHRP
UPT
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WVDHM
WXSBR
X7M
XV2
Y6R
YHG
ZGI
ZXP
ZZTAW
~8M
~S-
08R
AAJUZ
AAPBV
AAUGY
AAVGM
ABCVL
ABHUG
ABPTK
ABWRO
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TK
K9.
5PM
ID FETCH-LOGICAL-c5985-fc4f48246c3009d084930d412bafffcdaffae539eba68d34d9e7cfac8e86231f3
IEDL.DBID RPM
ISSN 0007-1188
IngestDate Tue Sep 17 21:08:56 EDT 2024
Thu Oct 10 19:52:24 EDT 2024
Fri Aug 23 00:36:31 EDT 2024
Sat Sep 28 07:59:41 EDT 2024
Sun Oct 22 16:07:41 EDT 2023
Sat Aug 24 00:44:46 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Rat
sphingolipids
sphingosine kinase
Cardiovascular disease
Vasomotricity
Sphingosine
Arterial pressure
Blood pressure
Hypertension
EDCF
Fingolimod
Enzyme
Transferases
Rodentia
Vasoconstriction
Sphingolipid
Endothelium
Immunomodulator
Vertebrata
Mammalia
Kinase
Animal
FTY720
Hemodynamics
Immunosuppressive agent
Language English
License CC BY 4.0
2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5985-fc4f48246c3009d084930d412bafffcdaffae539eba68d34d9e7cfac8e86231f3
OpenAccessLink https://europepmc.org/articles/pmc3417456?pdf=render
PMID 22251137
PQID 1545752005
PQPubID 42104
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3417456
proquest_journals_1545752005
crossref_primary_10_1111_j_1476_5381_2012_01865_x
pubmed_primary_22251137
pascalfrancis_primary_25934376
wiley_primary_10_1111_j_1476_5381_2012_01865_x_BPH1865
PublicationCentury 2000
PublicationDate June 2012
PublicationDateYYYYMMDD 2012-06-01
PublicationDate_xml – month: 06
  year: 2012
  text: June 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Basingstoke
– name: England
– name: London
PublicationTitle British journal of pharmacology
PublicationTitleAlternate Br J Pharmacol
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Nature Publishing Group
Publisher_xml – name: Blackwell Publishing Ltd
– name: Nature Publishing Group
References 2010; 10
2010; 16
2010; 207
2007a; 28
2011a; 6
2008; 9
2010; 362
1977; 41
2008; 1
2005; 48
2008; 585
2011; 39
2003; 278
2007; 109
2009; 158
2007; 35
2010; 62
2004; 309
2007b; 45
2010; 22
2006; 46
2010; 29
2011b; 6
2005; 96
2009; 284
2011; 163
2007; 21
2008; 153
2010; 74
2009; 104
2011; 164
2003; 284
17323789 - Int J Clin Pharmacol Ther. 2007 Feb;45(2):98-109
18026125 - Br J Pharmacol. 2008 Jan;153(1):140-7
21309759 - Br J Pharmacol. 2011 Jul;163(6):1140-62
20127284 - Mol Cells. 2010 Feb 28;29(2):105-11
14747617 - J Pharmacol Exp Ther. 2004 May;309(2):758-68
21818267 - PLoS One. 2011;6(7):e21817
18777003 - Basic Res Cardiol. 2009 Jan;104(1):50-9
13129923 - J Biol Chem. 2003 Nov 28;278(48):47408-15
862138 - Circ Res. 1977 Jul;41(1):19-26
20555359 - Nat Rev Cancer. 2010 Jul;10(7):489-503
16078855 - J Med Chem. 2005 Aug 11;48(16):5373-7
16855074 - J Clin Pharmacol. 2006 Aug;46(8):895-904
19812733 - Perspect Medicin Chem. 2007 Sep 06;1:11-23
21045200 - Drug Metab Dispos. 2011 Feb;39(2):199-207
22195025 - PLoS One. 2011;6(12):e29222
12742827 - Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2045-52
20584883 - J Exp Med. 2010 Jul 5;207(7):1475-83
22040146 - Br J Pharmacol. 2011 Nov;164 Suppl 1:S1-324
20548047 - Neurology. 2010 Jun 15;74(24):2022-4
20028707 - Mult Scler. 2010 Feb;16(2):197-207
20127285 - Mol Cells. 2010 Feb 28;29(2):99-104
18420192 - Eur J Pharmacol. 2008 May 13;585(2-3):292-302
17956243 - Biochem Soc Trans. 2007 Nov;35(Pt 5):908-9
18216770 - Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
20089952 - N Engl J Med. 2010 Feb 4;362(5):387-401
15802614 - Circ Res. 2005 Apr 29;96(8):913-20
17008548 - Blood. 2007 Feb 1;109(3):1077-85
17912702 - J Biochem Mol Toxicol. 2007;21(5):273-9
17230596 - Biopharm Drug Dispos. 2007 Mar;28(2):97-104
19119142 - J Biol Chem. 2009 Feb 27;284(9):5467-77
20089954 - N Engl J Med. 2010 Feb 4;362(5):402-15
20850539 - Pharmacol Res. 2010 Dec;62(6):465-74
19814729 - Br J Pharmacol. 2009 Nov;158(5):1173-82
20570726 - Cell Signal. 2010 Oct;22(10):1536-42
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_22_1
e_1_2_8_23_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
Adachi K (e_1_2_8_2_1) 2008; 1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 362
  start-page: 402
  year: 2010
  end-page: 415
  article-title: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
  publication-title: N Engl J Med
– volume: 1
  start-page: 11
  year: 2008
  end-page: 23
  article-title: FTY720 story. Its discovery and the following accelerated development of sphingosine 1‐phosphate receptor agonists as immunomodulators based on reverse pharmacology
  publication-title: Perspect Med Chem
– volume: 278
  start-page: 47408
  year: 2003
  end-page: 47415
  article-title: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
  publication-title: J Biol Chem
– volume: 45
  start-page: 98
  year: 2007b
  end-page: 109
  article-title: Ethnic sensitivity study of fingolimod in White and Asian subjects
  publication-title: Int J Clin Pharmacol Ther
– volume: 6
  start-page: e29222
  year: 2011b
  article-title: Antihypertensive treatment differentially affects vascular sphingolipid biology in spontaneously hypertensive rats
  publication-title: PLoS One
– volume: 48
  start-page: 5373
  year: 2005
  end-page: 5377
  article-title: Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer
  publication-title: J Med Chem
– volume: 41
  start-page: 19
  year: 1977
  end-page: 26
  article-title: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats
  publication-title: Circ Res
– volume: 585
  start-page: 292
  year: 2008
  end-page: 302
  article-title: Sphingolipid signalling in the cardiovascular system: good, bad or both?
  publication-title: Eur J Pharmacol
– volume: 109
  start-page: 1077
  year: 2007
  end-page: 1085
  article-title: The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A independently of sphingosine‐1‐phosphate receptors
  publication-title: Blood
– volume: 153
  start-page: 140
  year: 2008
  end-page: 147
  article-title: Analysis of sphingosine 1‐phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools
  publication-title: Br J Pharmacol
– volume: 35
  start-page: 908
  year: 2007
  end-page: 909
  article-title: The potential roles of sphingolipids in vascular smooth‐muscle function
  publication-title: Biochem Soc Trans
– volume: 16
  start-page: 197
  year: 2010
  end-page: 207
  article-title: Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3‐year results
  publication-title: Mult Scler
– volume: 10
  start-page: 489
  year: 2010
  end-page: 503
  article-title: Sphingosine 1‐phosphate and cancer
  publication-title: Nat Rev Cancer
– volume: 9
  start-page: 139
  year: 2008
  end-page: 150
  article-title: Principles of bioactive lipid signalling: lessons from sphingolipids
  publication-title: Nat Rev Mol Cell Biol
– volume: 163
  start-page: 1140
  year: 2011
  end-page: 1162
  article-title: Pharmacological relevance and potential of sphingosine 1‐phosphate in the vascular system
  publication-title: Br J Pharmacol
– volume: 284
  start-page: 5467
  year: 2009
  end-page: 5477
  article-title: FTY720 inhibits ceramide synthases and up‐regulates dihydrosphingosine 1‐phosphate formation in human lung endothelial cells
  publication-title: J Biol Chem
– volume: 207
  start-page: 1475
  year: 2010
  end-page: 1483
  article-title: Cell‐surface residence of sphingosine 1‐phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics
  publication-title: J Exp Med
– volume: 164
  start-page: S1
  issue: 1
  year: 2011
  end-page: S324
  article-title: Guide to Receptors and Channels (GRAC), 5th Edition
  publication-title: Br J Pharmacol
– volume: 309
  start-page: 758
  year: 2004
  end-page: 768
  article-title: Immune cell regulation and cardiovascular effects of sphingosine 1‐phosphate receptor agonists in rodents are mediated via distinct receptor subtypes
  publication-title: J Pharmacol Exp Ther
– volume: 62
  start-page: 465
  year: 2010
  end-page: 474
  article-title: Vessel‐specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries
  publication-title: Pharmacol Res
– volume: 96
  start-page: 913
  year: 2005
  end-page: 920
  article-title: Immunomodulator FTY720 induces eNOS‐dependent arterial vasodilatation via the lysophospholipid receptor S1P
  publication-title: Circ Res
– volume: 28
  start-page: 97
  year: 2007a
  end-page: 104
  article-title: Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects
  publication-title: Biopharm Drug Dispos
– volume: 104
  start-page: 50
  year: 2009
  end-page: 59
  article-title: Activation of sphingosine kinase by muscarinic receptors enhances NO‐mediated and attenuates EDHF‐mediated vasorelaxation
  publication-title: Basic Res Cardiol
– volume: 39
  start-page: 199
  year: 2011
  end-page: 207
  article-title: Absorption and disposition of the sphingosine 1‐phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways
  publication-title: Drug Metab Dispos
– volume: 158
  start-page: 1173
  year: 2009
  end-page: 1182
  article-title: FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system
  publication-title: Br J Pharmacol
– volume: 22
  start-page: 1536
  year: 2010
  end-page: 1542
  article-title: FTY720 and (S)‐FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen‐independent prostate cancer cells
  publication-title: Cell Signal
– volume: 362
  start-page: 387
  year: 2010
  end-page: 401
  article-title: A placebo‐controlled trial of oral fingolimod in relapsing multiple sclerosis
  publication-title: N Engl J Med
– volume: 29
  start-page: 99
  year: 2010
  end-page: 104
  article-title: Sphingosine‐1‐phosphate receptors: zooming in on ligand‐induced intracellular trafficking and its functional implications
  publication-title: Mol Cells
– volume: 6
  start-page: e21817
  year: 2011a
  article-title: Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide
  publication-title: PLoS One
– volume: 284
  start-page: H2045
  year: 2003
  end-page: H2052
  article-title: Sphingosine 1‐phosphate and control of vascular tone
  publication-title: Am J Physiol Heart Circ Physiol
– volume: 21
  start-page: 273
  year: 2007
  end-page: 279
  article-title: Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart
  publication-title: J Biochem Mol Toxicol
– volume: 29
  start-page: 105
  year: 2010
  end-page: 111
  article-title: Sphingolipids and the orchestration of endothelium‐derived vasoactive factors: when endothelial function demands greasing
  publication-title: Mol Cells
– volume: 74
  start-page: 2022
  year: 2010
  end-page: 2024
  article-title: Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis
  publication-title: Neurology
– volume: 46
  start-page: 895
  year: 2006
  end-page: 904
  article-title: FTY720: placebo‐controlled study of the effect on cardiac rate and rhythm in healthy subjects
  publication-title: J Clin Pharmacol
– ident: e_1_2_8_26_1
  doi: 10.1212/WNL.0b013e3181e3972b
– ident: e_1_2_8_8_1
  doi: 10.1111/j.1476-5381.2009.00451.x
– ident: e_1_2_8_11_1
  doi: 10.1152/ajpheart.01089.2002
– ident: e_1_2_8_35_1
  doi: 10.1124/dmd.110.035907
– ident: e_1_2_8_23_1
  doi: 10.1016/j.phrs.2010.09.002
– ident: e_1_2_8_25_1
  doi: 10.1111/j.1476-5381.2011.01260.x
– ident: e_1_2_8_9_1
  doi: 10.1056/NEJMoa0907839
– ident: e_1_2_8_4_1
  doi: 10.1016/j.ejphar.2008.02.089
– ident: e_1_2_8_18_1
  doi: 10.1161/01.RES.41.1.19
– ident: e_1_2_8_19_1
  doi: 10.1042/BST0350908
– ident: e_1_2_8_15_1
  doi: 10.1002/bdd.535
– ident: e_1_2_8_27_1
  doi: 10.1007/s10059-010-0042-y
– ident: e_1_2_8_22_1
  doi: 10.1038/sj.bjp.0707581
– ident: e_1_2_8_20_1
  doi: 10.1182/blood-2006-03-011437
– volume: 1
  start-page: 11
  year: 2008
  ident: e_1_2_8_2_1
  article-title: FTY720 story. Its discovery and the following accelerated development of sphingosine 1‐phosphate receptor agonists as immunomodulators based on reverse pharmacology
  publication-title: Perspect Med Chem
  contributor:
    fullname: Adachi K
– ident: e_1_2_8_5_1
  doi: 10.1111/j.1476-5381.2011.01649_1.x
– ident: e_1_2_8_6_1
  doi: 10.1074/jbc.M805186200
– ident: e_1_2_8_21_1
  doi: 10.1038/nrc2875
– ident: e_1_2_8_33_1
  doi: 10.1007/s10059-010-0041-z
– ident: e_1_2_8_31_1
  doi: 10.1161/01.RES.0000164321.91452.00
– ident: e_1_2_8_30_1
  doi: 10.1084/jem.20091343
– ident: e_1_2_8_17_1
  doi: 10.1007/s00395-008-0744-x
– ident: e_1_2_8_16_1
  doi: 10.5414/CPP45098
– ident: e_1_2_8_14_1
  doi: 10.1056/NEJMoa0909494
– ident: e_1_2_8_29_1
  doi: 10.1371/journal.pone.0029222
– ident: e_1_2_8_34_1
  doi: 10.1002/jbt.20193
– ident: e_1_2_8_10_1
  doi: 10.1177/1352458509357065
– ident: e_1_2_8_7_1
  doi: 10.1074/jbc.M307687200
– ident: e_1_2_8_24_1
  doi: 10.1177/0091270006289853
– ident: e_1_2_8_32_1
  doi: 10.1016/j.cellsig.2010.05.022
– ident: e_1_2_8_28_1
  doi: 10.1371/journal.pone.0021817
– ident: e_1_2_8_3_1
  doi: 10.1021/jm050242f
– ident: e_1_2_8_13_1
  doi: 10.1038/nrm2329
– ident: e_1_2_8_12_1
  doi: 10.1124/jpet.103.062828
SSID ssj0014775
Score 2.2050202
Snippet BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical...
FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical trials have demonstrated...
BACKGROUND AND PURPOSE FTY720 (Fingolimod) is a recently approved orally administered drug for the treatment of multiple sclerosis. Phase II and III clinical...
SourceID pubmedcentral
proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1411
SubjectTerms Animals
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood
Blood and lymphatic vessels
Blood Pressure - drug effects
Cardiology. Vascular system
Carotid Arteries - cytology
Carotid Arteries - drug effects
Carotid Arteries - metabolism
Carotid Arteries - pathology
Cyclooxygenase Inhibitors - pharmacology
EDCF
Endothelium
Endothelium, Vascular - cytology
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Endothelium, Vascular - pathology
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Fingolimod
Fingolimod Hydrochloride
FTY720
hypertension
Hypertension - chemically induced
Hypertension - metabolism
Hypertension - pathology
Hypertension - physiopathology
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - chemistry
Immunosuppressive Agents - pharmacology
Isoenzymes - antagonists & inhibitors
Isoenzymes - metabolism
Kinases
Male
Medical sciences
Muscle, Smooth, Vascular - cytology
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - metabolism
Muscle, Smooth, Vascular - pathology
Pharmacology. Drug treatments
Phosphorylation
Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors
Phosphotransferases (Alcohol Group Acceptor) - metabolism
Propylene Glycols - adverse effects
Propylene Glycols - chemistry
Propylene Glycols - pharmacology
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Research Papers
Rodents
sphingolipids
Sphingosine - adverse effects
Sphingosine - analogs & derivatives
Sphingosine - chemistry
Sphingosine - pharmacology
sphingosine kinase
Thromboxane A2 - antagonists & inhibitors
Thromboxane A2 - metabolism
Vascular Resistance - drug effects
vasoconstriction
Vasoconstrictor Agents - adverse effects
Vasoconstrictor Agents - chemistry
Vasoconstrictor Agents - pharmacology
SummonAdditionalLinks – databaseName: Wiley-Blackwell
  dbid: 33P
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LitswFL20syqUvh-eTgctytDCuNiRbMnLPiaELkqgKbQrIetBzAzOEDfQ_MB8d--V8xi3syilmxASyQ_lXOtc5dwjgFdZrlwoqjqtTOZTYSRP60yEtK7qIGmbzGCpOHnyRX7-pj6ekU3Op20tTO8PsVtwo8iIz2sKcFN3vwW5LFMMWErzaEkvV2XxlvgkJg2xmoNPd38oCCn7zQzIEzFXaijqufFAg5nq7qXpcNBCv9vFTXT0T1XldbYbp6vx_f95ow_g3oa0snc9yh7CLd8-gpNp73q9PmWzfRFXd8pO2HTvh71-DFfj2Xc5ytjrgNPk4gLB4d6wpiW62vmObbWwjGzBmWkdi2J6FhW6q6XHpox0vMhi_WLVXazZHHPn5UZ5zxDBeIzGYLN5U0cBGlsE7EFLawtS9bPzpsUzPYGv47PZh0m62f4htUWlijRYEYQaidJyJIIuU6LimRP5qDYhBOvw1fiCV742pXJcuMpLG4xVHrM0ngf-FA5avPLnwJzg0uZBhdIqmoBrRSXLBkFpkWH6PIF8-1Pry97lQ1_PjmSpafg1Db-Ow69_JnA8wMSuIyaUHM9XJnC0BYnePBg6TYxVktVVkcCzHi_7jiPK97hMQA6QtGtAVuDDb9pmHi3BkYtIpMIJlBFJf30T-v10Qu8O_7XjC7hDH_fiuSM4-LFc-Zdwu3Or4xiAvwBUVTJR
  priority: 102
  providerName: Wiley-Blackwell
Title FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1476-5381.2012.01865.x
https://www.ncbi.nlm.nih.gov/pubmed/22251137
https://www.proquest.com/docview/1545752005
https://pubmed.ncbi.nlm.nih.gov/PMC3417456
Volume 166
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1di9NAFB3sPgkifhtdyzzIorDZZjqTzORRd7dURAlYQZ9CMh80bDctjYXtH9jf7b2TZNuiD-JLCGQmk-TeyT03OXMuIW8jpoyL0zJMi8iGopA8LCPhwjItncQymU7j4uTpN_n1h7q4RJmcuF8L40n7uqzO6sX1WV3NPbdyda1HPU9slH05hzevhMA_GpABYMM-Re9-HQgp27IFqH7IlDqk7wiZhDDHMTPEr4BMJbHXosa0hzGshr4Xnh6sigaelGtLXPwNg_5JpdyHuD5GTR6Rhx24pB_am3hM7tn6CTnJWnXq7Smd7RZbNaf0hGY73ertU3I7mf2U44i-cxDOlgswonlPqxphZWMb2nNWKcp306I21JPeqWfSbtYWmlLk2wLatMtNs9jSOeS4644hT8HT4BxVAc3mVemJYnTpoAd-Alsi-55eVTWM9Ix8n1zOzqdhV6Yh1HGq4tBp4YQai0RzAGwmUiLlkRFsXBbOOW1gW9iYp7YsEmW4MKmV2hVaWcimOHP8OTmq4cpfEmoEl5o55RKtMFCWCpcWF-A8GpCgZQFhvXXyVavGke9nMTLJ0bg5Gjf3xs1vAjI8MONdR0j8OIyXBOS4t2veTeAmR2QpUZIqDsiL1sS7jp2vBEQeGP-uAUp2Hx4BT_bS3Z3nBiTxbvLPN5F_zKa49-q_h3xN7uMJW5bbMTn6td7YN2TQmM2QDDjPYHvx6fPQz6XfEkUgeA
link.rule.ids 230,315,729,782,786,887,1408,27935,27936,46066,46490,53803,53805
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFD6C8QDSxB0WGMMPaAJpQUntxM4jl1VFG1MligRPluOLGjGlU0Ml-gf43ZyT9LLAHhDipYpUO2mc78TfcT9_B-BFkioXsqKMC5P4WBjJ4zIRIS6LMkgqkxksbU4efZJnX9T7Y7LJOVnvhen8ITYLbhQZ7fuaApwWpH-LcpnHGLGU59GaXqry7DUSyhsiFwXVceB8vPlLQUjZlTMgV8RUqb6s58oz9eaq3QvT4LCFrt7FVYT0T13lZb7bTljDO__1Vu_C7RVvZW86oN2Da76-D4fjzvh6ecQm231czRE7ZOOtJfbyAfwcTr7KQcJeBpwpZ-eID_eKVTUx1sY3bC2HZeQMzkztWKunZ61IdzH32JSRlBeJrJ8tmvMlm2L6PF-J7xmCGM9RGWw2rcpWg8ZmAXvQ6tqMhP3sW1XjlR7C5-Hx5N0oXlWAiG1WqCwOVgShBiK3HLmgS5QoeOJEOihNCME6_DQ-44UvTa4cF67w0gZjlcdEjaeBP4KdGn_5HjAnuLRpUCG3iubgUtGuZYO4tEgyfRpBun7W-qIz-tCXEySZaxp-TcOv2-HXPyI46IFi0xFzSo7XyyPYX6NEr94NjSbSKsntKovgcQeYbccBpXxcRiB7UNo0IDfw_jd1NW1dwZGOSGTDEeQtlP76JvTb8YiOnvxrx-dwczT5eKpPP5ydPIVb1KTT0u3Dzvf5wj-D641bHLTR-At83jZy
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9NAFD7oCiKI90t0XedBFoXNknQmmcmjulvqhaVgBX0aJnOhwSUtjQX7B_zdnpP0stF9EPGlBDqTNJPvZL4z_c43AC-SVLmQFWVcmMTHwkgel4kIcVmUQdI2mcFScfLokzz7ok5OySbn_aYWpvOH2C64UWS072sK8LkLvwW5zGMMWErzaEkvVXl2jHzymiBWTuUcfLz9R0FI2e1mQKaIqVJ9Vc-lZ-pNVTfnpsFRC912F5fx0T9llRfpbjtfDW__zzu9A7fWrJW97mB2F674-h4cjjvb69URm-yquJojdsjGO0Ps1X34OZx8lYOEvQw4T87OER3uFatq4quNb9hGDMvIF5yZ2rFWTc9aie5y4bEpIyEv0lg_WzbnKzbF5Hmxlt4zhDCeozLYbFqVrQKNzQL2oLW1Gcn62beqxis9gM_D08nbUbze_yG2WaGyOFgRhBqI3HJkgi5RouCJE-mgNCEE6_DT-IwXvjS5cly4wksbjFUe0zSeBv4Q9mr85Y-BOcGlTYMKuVU0A5eKapYNotIixfRpBOnmUet5Z_OhL6ZHMtc0_JqGX7fDr39EcNDDxLYjZpQcr5dHsL8BiV6_GRpNlFWS11UWwaMOL7uOA0r4uIxA9pC0bUBe4P1v6mraeoIjGZHIhSPIWyT99U3oN-MRHT35147P4fr4ZKg_vjv78BRuUItOSLcPe98XS_8MrjZuedDG4i-mgjUh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FTY720+%28fingolimod%29+increases+vascular+tone+and+blood+pressure+in+spontaneously+hypertensive+rats+via+inhibition+of+sphingosine+kinase&rft.jtitle=British+journal+of+pharmacology&rft.au=Spijkers%2C+L%C3%A9on+JA&rft.au=Alewijnse%2C+Astrid+E&rft.au=Peters%2C+Stephan+LM&rft.date=2012-06-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=166&rft.issue=4&rft.spage=1411&rft.epage=1418&rft_id=info:doi/10.1111%2Fj.1476-5381.2012.01865.x&rft.externalDBID=10.1111%252Fj.1476-5381.2012.01865.x&rft.externalDocID=BPH1865
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon